WO2023033130A1 - Composition pour le traitement ou la prévention de maladies osseuses - Google Patents
Composition pour le traitement ou la prévention de maladies osseuses Download PDFInfo
- Publication number
- WO2023033130A1 WO2023033130A1 PCT/JP2022/033056 JP2022033056W WO2023033130A1 WO 2023033130 A1 WO2023033130 A1 WO 2023033130A1 JP 2022033056 W JP2022033056 W JP 2022033056W WO 2023033130 A1 WO2023033130 A1 WO 2023033130A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- siglec
- composition
- bone
- secretory
- secreted
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- 208000020084 Bone disease Diseases 0.000 title claims abstract description 29
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 claims abstract description 108
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 claims abstract description 105
- 230000003248 secreting effect Effects 0.000 claims abstract description 49
- 210000002997 osteoclast Anatomy 0.000 claims abstract description 40
- 230000004069 differentiation Effects 0.000 claims abstract description 25
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 24
- 230000037182 bone density Effects 0.000 claims abstract description 22
- 230000001965 increasing effect Effects 0.000 claims abstract description 13
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 39
- 208000001132 Osteoporosis Diseases 0.000 claims description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 230000028709 inflammatory response Effects 0.000 claims description 15
- 208000010392 Bone Fractures Diseases 0.000 claims description 8
- 230000017074 necrotic cell death Effects 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 101710197064 Lectin 9 Proteins 0.000 claims description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 210000002798 bone marrow cell Anatomy 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 210000000988 bone and bone Anatomy 0.000 description 20
- 238000000034 method Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 238000011282 treatment Methods 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 12
- 206010003246 arthritis Diseases 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 9
- 210000000845 cartilage Anatomy 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000006378 damage Effects 0.000 description 8
- 102000014128 RANK Ligand Human genes 0.000 description 7
- 108010025832 RANK Ligand Proteins 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 206010017076 Fracture Diseases 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000000544 articulatio talocruralis Anatomy 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 206010051728 Bone erosion Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 4
- 101710127797 Macrophage colony-stimulating factor 1 Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000009806 oophorectomy Methods 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 102000004171 Cathepsin K Human genes 0.000 description 3
- 108090000625 Cathepsin K Proteins 0.000 description 3
- -1 IL-1β Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 206010023203 Joint destruction Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 102000045929 human SIGLEC9 Human genes 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000010603 microCT Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000001258 synovial membrane Anatomy 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101150011252 CTSK gene Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 101100396994 Drosophila melanogaster Inos gene Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 101000711846 Homo sapiens Transcription factor SOX-9 Proteins 0.000 description 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010043267 Sp7 Transcription Factor Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 102100034204 Transcription factor SOX-9 Human genes 0.000 description 2
- 102100032317 Transcription factor Sp7 Human genes 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003367 anti-collagen effect Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 210000000458 cuboid bone Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 229960001251 denosumab Drugs 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- GMTYREVWZXJPLF-AFHUBHILSA-N butorphanol D-tartrate Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-AFHUBHILSA-N 0.000 description 1
- 229960001590 butorphanol tartrate Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 229960004882 medetomidine hydrochloride Drugs 0.000 description 1
- VPNGEIHDPSLNMU-UHFFFAOYSA-N medetomidine hydrochloride Chemical compound Cl.C=1C=CC(C)=C(C)C=1C(C)C1=CNC=N1 VPNGEIHDPSLNMU-UHFFFAOYSA-N 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 description 1
- 229950011129 minodronic acid Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- 229950010968 romosozumab Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Rheumatology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Les présents inventeurs ont découvert que la Siglec-9 sécrétoire inhibe la différenciation des cellules de la moelle osseuse et des macrophages en ostéoclastes et augmente la densité minérale osseuse, et que la Siglec-9 sécrétoire inhibe la réaction inflammatoire des fibroblastes. Par conséquent, la présente divulgation concerne une composition qui est destinée au traitement ou à la prévention de maladies osseuses, et qui contient de la Siglec-9 sécrétoire. Dans un autre mode de réalisation, la présente divulgation concerne une composition qui est destinée à l'augmentation de la densité minérale osseuse, et qui contient de la Siglec-9 sécrétoire. Dans encore un autre mode de réalisation, la présente divulgation concerne une composition qui est destinée à la prévention de fracture, et qui contient de la Siglec-9 sécrétoire. Dans encore un autre mode de réalisation, la présente divulgation concerne une composition qui est destinée à l'inhibition de la différenciation en ostéoclastes, et qui contient de la Siglec-9 sécrétoire. Dans encore un autre mode de réalisation, la présente divulgation concerne une composition qui est destinée à l'inhibition de la réaction inflammatoire de fibroblastes, et qui contient de la Siglec-9 sécrétoire.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023508573A JPWO2023033130A1 (fr) | 2021-09-03 | 2022-09-02 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021144208 | 2021-09-03 | ||
| JP2021-144208 | 2021-09-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023033130A1 true WO2023033130A1 (fr) | 2023-03-09 |
Family
ID=85412433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2022/033056 WO2023033130A1 (fr) | 2021-09-03 | 2022-09-02 | Composition pour le traitement ou la prévention de maladies osseuses |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPWO2023033130A1 (fr) |
| WO (1) | WO2023033130A1 (fr) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015166694A (ja) * | 2014-03-03 | 2015-09-24 | 国立大学法人名古屋大学 | 幹細胞の培養産物の評価指標及びその利用 |
| JP2019500014A (ja) * | 2015-10-29 | 2019-01-10 | アレクトル エルエルシー | 抗Ｓｉｇｌｅｃ−９抗体及びその使用方法 |
| WO2019230859A1 (fr) * | 2018-05-31 | 2019-12-05 | 国立大学法人徳島大学 | Procédé pour le traitement et/ou la prévention de l'ostéoarthrite |
-
2022
- 2022-09-02 WO PCT/JP2022/033056 patent/WO2023033130A1/fr unknown
- 2022-09-02 JP JP2023508573A patent/JPWO2023033130A1/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015166694A (ja) * | 2014-03-03 | 2015-09-24 | 国立大学法人名古屋大学 | 幹細胞の培養産物の評価指標及びその利用 |
| JP2019500014A (ja) * | 2015-10-29 | 2019-01-10 | アレクトル エルエルシー | 抗Ｓｉｇｌｅｃ−９抗体及びその使用方法 |
| WO2019230859A1 (fr) * | 2018-05-31 | 2019-12-05 | 国立大学法人徳島大学 | Procédé pour le traitement et/ou la prévention de l'ostéoarthrite |
Non-Patent Citations (8)
| Title |
|---|
| ABE FUMIHIKO, TAKAHASHI HARUKA, TANAKA AKIRA: "Investigation on the Action and Effect of Culture Supernatant of Human Dental Pulp Stem Cells Using Rats with Medication-Related Osteonecrosis of the Jaw", JOURNAL OF HARD TISSUE BIOLOGY, vol. 28, no. 4, 1 January 2019 (2019-01-01), pages 349 - 358, XP093042364, ISSN: 1341-7649 * |
| ANDES F.T.; ADAM S.; HAHN M.; AUST O.; FREY S.; GRUENEBOOM A.; NITSCHKE L.; SCHETT G.; STEFFEN U.: "The human sialic acid-binding immunoglobulin-like lectin Siglec-9 and its murine homolog Siglec-E control osteoclast activity and bone resorption", BONE, PERGAMON PRESS., OXFORD, GB, vol. 143, 30 September 2020 (2020-09-30), GB , XP086422174, ISSN: 8756-3282, DOI: 10.1016/j.bone.2020.115665 * |
| HUSTON M., INGHAM J., COLLARD B.: "An extra tablet for safety", INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, COPENHAGEN, DK, vol. 46, 1 March 2017 (2017-03-01), DK , pages 344 - 345, XP093042366, ISSN: 0901-5027, DOI: 10.1016/j.ijom.2017.02.1162 * |
| ISHIKAWA JUN; KANO FUMIYA; ANDO YUJI; HIBI HIDEHARU; YAMAMOTO AKIHITO: "Monocyte chemoattractant protein-1 and secreted ectodomain of sialic acid-binding Ig-like lectin-9 enhance bone regeneration by inducing M2 macrophages", JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, MEDICINE, AND PATHOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 31, no. 3, 1 January 1900 (1900-01-01), AMSTERDAM, NL , pages 169 - 174, XP085682427, ISSN: 2212-5558, DOI: 10.1016/j.ajoms.2018.12.007 * |
| ISHIKAWA JUN; TAKAHASHI NOBUNORI; MATSUMOTO TAKUYA; YOSHIOKA YUTAKA; YAMAMOTO NORIYUKI; NISHIKAWA MASAYA; HIBI HIDEHARU; ISHIGRO N: "Factors secreted from dental pulp stem cells show multifaceted benefits for treating experimental rheumatoid arthritis", BONE, PERGAMON PRESS., OXFORD, GB, vol. 83, 19 November 2015 (2015-11-19), GB , pages 210 - 219, XP029385167, ISSN: 8756-3282, DOI: 10.1016/j.bone.2015.11.012 * |
| MAEDA, AYAKO ET AL.: "P-035 Improvement of the bone resorption by condition medium of SHED in ovariectomized mice", SHONI-SHIKAGAKU-ZASSHI : OFFICIAL PUBLICATION OF THE JAPANESE SOCIETY OF PEDIATRIC DENTISTRY = THE JAPANESE JOURNAL OF PEDIATRIC DENTISTRY, NIHON SHONI SHIKA GAKKAI,, JP, vol. 56, no. 2, 1 January 2018 (2018-01-01), JP , pages 227, XP009544165, ISSN: 0583-1199 * |
| MATSUMOTO TAKUYA, TAKAHASHI NOBUNORI, KOJIMA TOSHIHISA, YOSHIOKA YUTAKA, ISHIKAWA JUN, FURUKAWA KOICHI, ONO KENJI, SAWADA MAKOTO, : "Soluble Siglec-9 suppresses arthritis in a collagen-induced arthritis mouse model and inhibits M1 activation of RAW264.7 macrophages", ARTHRITIS RESEARCH & THERAPY, vol. 18, no. 1, 1 December 2016 (2016-12-01), XP093042368, DOI: 10.1186/s13075-016-1035-9 * |
| SONODA SOICHIRO, MURATA SARA, NISHIDA KENTO, KATO HIROKI, UEHARA NORIHISA, KYUMOTO YUKARI N., YAMAZA HARUYOSHI, TAKAHASHI ICHIRO, : "Extracellular vesicles from deciduous pulp stem cells recover bone loss by regulating telomerase activity in an osteoporosis mouse model", STEM CELL RESEARCH & THERAPY, vol. 11, no. 1, 1 December 2020 (2020-12-01), XP093042370, DOI: 10.1186/s13287-020-01818-0 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2023033130A1 (fr) | 2023-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8158589B2 (en) | Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1) | |
| US20190203209A1 (en) | Method of Modulating Fibroblast Accumulation or Collagen Deposition | |
| US20060003932A1 (en) | Method for promoting neovascularization | |
| JP2021518745A (ja) | アクチビンｉｉｂ型受容体変異体およびそれらの使用方法 | |
| US8536128B2 (en) | Granulin/epithelin precursor (GEP), a chondrogenic growth factor and target in cartilage disorders | |
| JP2009538274A (ja) | Ｃｘｃｌ１３またはｃｘｃｒ５のアンタゴニストの創傷または線維症疾患の治療のための使用 | |
| WO2012162215A1 (fr) | Promotion de la cicatrisation de fracture à l'aide d'inhibiteurs du complément | |
| KR20160118264A (ko) | 스테로이드제 투여로 유발되는 성장 장해에 대한 의약 | |
| KR20150013455A (ko) | 골 수복 촉진제 | |
| KR20030016254A (ko) | 죽상경화증의 치료 또는 예방을 위한 ｉｌ-18 저해물질의용도 | |
| US9725484B2 (en) | Methods and compositions for the treatment of bone remodeling disorders | |
| US8871900B2 (en) | Fibroblast growth factor (FGF) analogs and uses thereof | |
| EP1358888A1 (fr) | L'Antibiotique peptidique humain LL-37/hCAP-18 est un inducteur de l'angiogénèse | |
| WO2023033130A1 (fr) | Composition pour le traitement ou la prévention de maladies osseuses | |
| US20070098722A1 (en) | Medicament comprising inhibitors of long pentraxin ptx3 | |
| EP1261364A1 (fr) | Procede destine a traiter ou a inhiber des lesions ou des morts cellulaires | |
| Wahl et al. | Ethanol‐induced inhibition of bone formation in a rat model of distraction osteogenesis: a role for the tumor necrosis factor signaling axis | |
| Laurent et al. | TGF-beta antibodies: a novel treatment for pulmonary fibrosis? | |
| EP2606905A1 (fr) | Peptides ciblant le recepteur activateur du facteur nuclear-kappa B (RANK) et leurs applications | |
| US20060275303A1 (en) | Modulating angiogenesis using LL-37/HCAP-18 | |
| KR20130014700A (ko) | Ｖｅｇｆ 발현을 증가시키는 신규한 펩타이드 및 이를 함유하는 약학적 조성물 | |
| Andrews | Progress in RANK ligand biology: bone and beyond | |
| JP2011513434A (ja) | キメラＣ３様Ｒｈｏアンタゴニストによる骨治療 | |
| US20120076754A1 (en) | Use of IL-17 Polypeptides for Use in the Prevention or Treatment of Atherosclerosis | |
| JPWO2008078588A1 (ja) | 関節軟骨の変性を治療又は予防するための医薬及び方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENP | Entry into the national phase |
Ref document number: 2023508573 Country of ref document: JP Kind code of ref document: A |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22864712 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |